Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotech company, has announced a partnership with Hoth Therapeutics (NASDAQ: HOTH) to deploy its AI-powered platform, PredictBBB.ai, in streamlining drug development. The platform, which boasts 94% accuracy, predicts whether drug candidates can cross the blood-brain barrier—a major challenge in developing treatments for neurological conditions. By integrating PredictBBB.ai, Hoth aims to reduce development risk, improve candidate selection, and accelerate timelines.
PredictBBB.ai is part of Lantern’s broader RADR platform, which applies AI and machine learning to optimize oncology drug discovery and development. RADR leverages over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms to help solve real-world problems in oncology drug development. According to the company, Lantern’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years at approximately $2.5 million per program.
The collaboration is expected to significantly impact the development of therapies for central nervous system (CNS) disorders, where the blood-brain barrier often limits drug efficacy. By using PredictBBB.ai, Hoth Therapeutics can prioritize drug candidates with a higher likelihood of reaching the brain, thereby reducing the time and cost associated with clinical trials. Leaders from both companies highlighted the collaboration as a pivotal step toward accelerating the path to bring life-changing therapies to patients.
For more details, the full announcement is available at https://ibn.fm/NZoZD. Additional information about Lantern Pharma and its news can be found at https://ibn.fm/LTRN.
This partnership underscores the growing role of artificial intelligence in drug discovery, particularly in addressing complex biological barriers. As AI platforms like PredictBBB.ai demonstrate high accuracy, they are becoming essential tools for biotech companies seeking to reduce attrition rates and bring effective therapies to market more efficiently. The collaboration between Lantern Pharma and Hoth Therapeutics exemplifies how AI can transform the cost, pace, and timeline of drug development, ultimately benefiting patients in need of innovative treatments.
